Published : 15 Oct 2024

---

Aagami has received another contract extension from Japanese client specialising in Nose to Brain delivery.. 

The client has unlocked efficient delivery to the olfactory region. 

Their assets are focused on Age-Related Diseases including, 

• Frontotemporal Dementia (Orphan Drug Designation granted by US FDA)

• Alzheimer’s Disease

• Parkinson’s Disease

• Anti Depression and ALS 

Aagami is supporting the client to find investments/strategic partnerships. 

Aagami will also represent the client in the upcoming JP Morgan Healthcare Week and Biotech Showcase in Jan 2025 in San Francisco